A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer

Afatinib (also known as BIBW 2992) has recently been approved in several countries for the treatment of a distinct type of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. This manuscript comprehensively reviews the preclinical data on afatinib, an irreversible inhibitor o...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Modjtahedi, Helmout, Cho, Byoung Chul, Michel, Martin C., Solca, Flavio
Формат: Artigo
Язык:Inglês
Опубликовано: Springer Berlin Heidelberg 2014
Предметы:
Review
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4019832/
https://ncbi.nlm.nih.gov/pubmed/24643470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00210-014-0967-3
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы